奥拉西坦注射液治疗一氧化碳中毒迟发性脑病患者的临床研究  

Clinical trial of oxiracetam injection in the treatment of patients with delayed encephalopathy after acute carbon monoxide poisoning

作　　者：王克宇[1] 才立云[1] 郭佳 WANG Ke-yu;CAI Li-yun;GUO Jia(Department of Emergency Medicine,Tangshan Gongren Hospital,Tangshan 063000,Hebei Province,China)

机构地区：[1]唐山市工人医院急诊内科,河北唐山063000

出　　处：《中国临床药理学杂志》2022年第11期1170-1173,共4页The Chinese Journal of Clinical Pharmacology

基　　金：河北省医学科学研究重点课题计划资助项目(20181268)。

摘　　要：目的观察奥拉西坦注射液治疗一氧化碳中毒迟发性脑病患者的临床疗效和安全性。方法将94例一氧化碳中毒迟发性脑病患者随机分为对照组46例和试验组48例。对照组给予高压氧治疗;试验组在对照组治疗的基础上,给予奥拉西坦注射液4.0 g,静脉滴注,每天1次。2组患者均持续治疗2周。比较2组患者的临床疗效,蒙特利尔认知评估表(MoCA)、简易精神状态检查表(MMSE)和日常生活活动能力(ADL)评分,以及药物不良反应的发生情况。结果试验过程中共脱落8例。治疗后,试验组和对照组的总有效率分别为95.56%(43例/45例)和78.05%(32例/41例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的MoCA评分分别为(28.36±3.80)和(25.81±4.35)分,MMSE评分分别为(24.01±4.86)和(20.45±4.11)分,ADL评分分别为(80.06±10.63)和(71.58±11.41)分,差异均有统计学意义(均P<0.05)。试验组的药物不良反应主要有头晕、恶心和耳痛,对照组的药物不良反应主要有头晕和耳痛。试验组和对照组的总药物不良反应发生率分别为6.67%和4.88%,差异无统计学意义(P>0.05)。结论奥拉西坦注射液治疗一氧化碳中毒迟发性脑病患者的临床疗效确切,其能显著提高患者的认知功能和生活质量,且不增加药物不良反应的发生率。Objective To observe the clinical efficacy and safety of oxiracetam injection in the treatment of patients with delayed encephalopathy after acute carbon monoxide poisoning.Methods Ninety-four patients with delayed encephalopathy after acute carbon monoxide poisoning were randomly divided into control group(n=46 cases)and treatment group(n=48 cases).The control group was treated with hyperbaric oxygen;on this basis of control group,the treatment group was treated with oxiracetam injection 4.0 g,intravenous drip,once a day.The two groups were treated for 2 weeks.The clinical efficacy,Montreal Cognitive Assessment Scale(MoCA),Mini-Mental State Examination(MMSE)and activities of daily living(ADL)scores,and adverse drug reactions were compared between two groups.Results A total of 8 cases were dropped off during the trial.After treatment,the total effective rates of treatment and control groups were 95.56%(43 cases/45 cases)and 78.05%(32 cases/41 cases)with significant difference(P<0.05).After treatment,the MoCA scores of treatment and control groups were(28.36±3.80)and(25.81±4.35),MMSE scores were(24.01±4.86)and(20.45±4.11),ADL scores were(80.06±10.63)and(71.58±11.41),the differences were statistically significant(all P<0.05).The adverse drug reactions of treatment group were dizziness,nausea and earache,which in the control group were dizziness and earache.The total incidences of adverse drug reactions in the treatment and control groups were 6.67%and 4.88%without significant difference(P>0.05).Conclusion Oxiracetam injection has definitive clinical efficacy in the treatment of patients with delayed encephalopathy after acute carbon monoxide poisoning,which can improve cognitive function and quality of life,without increasing the incidence of adverse drug reactions.

关 键 词：奥拉西坦注射液 一氧化碳中毒迟发性脑病 D-二聚体 心肌肌钙蛋白Ⅰ 安全性评价 

分 类 号：R977[医药卫生—药品]